Please login to the form below

IBD

This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

investigational IBD medicines.

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Sponsored by Cloud Talk. Winner: LOGIC IBD Nurse Education and Recognition Event.
Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Tremfya also has data suggesting it works in Stelara-resistant psoriasis. Lilly’s antibody is still in phase 3 for psoriasis, well behind the leaders, but IBD presents a greater opportunity
Finch’s microbiota drug for C. diff gets FDA breakthrough status

Finch's CEO Mark Smith. Led by CEO Mark Smith, the company also has a two-year-old deal with Takeda to develop a microbiota treatment for irritable bowel disease (IBD).
BMS to test Vedanta’s bacterial therapy with Opdivo

The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in
Communiqué: big wins for obesity and sugar tax campaigners

Specialist healthcare communications group Sciterion (pictured below) won the Excellence in Communications via a Live Event or Stand-Alone Activity accolade for its Live Multi-site National IBD Meeting. ... Meanwhile, Aurora Healthcare Communications’

More from news
Approximately 11 fully matching, plus 32 partially matching documents found.

Gut instincts lead Takeda to GI pipeline success

It has been a game changer for IBD patients and the EMA decision means that they have greater choice. ... Projects that address gut inflammation beyond IBD are focused on coeliac disease, acute pancreatitis and short bowel syndrome.
Case study: Logic IBD Nurse Education Day and Recognition Event

The solution was a dual-aspect meeting: The ‘LOGIC IBD Nurse Education Day and Recognition Event’. ... IBD nurses had limited support with personal development and raising their profile within their hospital/Trust.
Case study: IBD Registry Roadshow

It was originally planned to run alongside a successful national IBD Audit programme managed by the Royal College of Physicians (RCP). ... In 2015 NHS England announced it was pulling the Audit funding and recommended that future audits be incorporated
Deal Watch February 2017

The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)
Deal Watch June 2016

IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.

More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.

Takeda strengthens leadership team with business unit director

Takeda UK has appointed Craig Adkins as its new business unit director for irritable bowel disease (IBD). .

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

July 2020: diversity and inclusion in clinical trials round-up

Asians. Health outcomes for IBD are poorer among African Americans vs white Americans. ... In some cultures, an IBD diagnosis is associated with stigma, which can impact the patient journey.
Lucid Group bolsters its senior client services team with two magical new hires

She has experience across several different therapy areas, including diabetes, rare diseases and IBD.
Lucid Group strengthens its scientific leadership and client service team with two new hires

Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno-oncology, CIA, CKD, oral contraception, IBD, and wound care.
IBD Registry appoints first CEO

The IBD Registry is familiar to many as the first UK-wide collection of anonymised adult and paediatric IBD data for prospective audit and research. ... Liz brings to the IBD Registry 20 years of executive and senior management experience from the
Pharma and NHS working together for patients - the IBD Registry Industry Working Group

Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile.

More from PMHub
Approximately 3 fully matching, plus 19 partially matching documents found.

Add my company

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...